Context Recent randomized controlled trials (RCTs) examined the role of adding androgen
receptor signaling inhibitors (ARSIs), including abiraterone acetate (ABI), apalutamide …

Androgen deprivation therapy (ADT) alone has been the cornerstone of treatment for
patients with newly diagnosed metastatic prostate cancer for the past century. Based on …

Context Androgen receptor signaling inhibitor (ARSi) agents are emerging as standard
treatments for prostate cancer across the disease spectrum, but much remains unknown …

Importance Cardiovascular (CV) events remain a substantial cause of mortality among men
with advanced and metastatic prostate cancer (PCa). The introduction of novel androgen …

Abstract Context Randomized controlled trials (RCTs) have shown that addition of docetaxel
or androgen receptor axis–targeted therapy (ARAT) to androgen deprivation therapy (ADT) …

Background Multiple oral chemotherapeutic agents for metastatic hormone-sensitive
prostate cancer (mHSPC) have been developed for conjugated use with conventional …

Purpose: To perform a systematic review and network meta-analysis to compare the efficacy
and safety of currently available docetaxel-based systemic triplet therapies for metastatic …

Background and objective Currently available post hoc phase 3 trial–derived data suggest
better cancer-control outcomes in apalutamide-treated metastatic hormone-sensitive …

Purpose This study investigated the impact of treatment intensification with upfront docetaxel
(DOC) or abiraterone (ABI) plus prednisolone on survival outcomes in patients with …

Simple Summary Despite the use of surgery and treatments that inhibit the androgen axis
signaling, prostate cancer patients invariably become resistant to castration. In the case of …